Tolvaptan inhibition of desmopressin effects on coagulation factors in a patient with decreased von Willebrand factor and polycystic kidney disease

Blood. 2011 Jul 14;118(2):474-6. doi: 10.1182/blood-2011-04-347328.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Benzazepines / pharmacology*
  • Benzazepines / therapeutic use
  • Blood Coagulation / drug effects*
  • Blood Coagulation Factors / drug effects
  • Blood Coagulation Factors / metabolism*
  • Deamino Arginine Vasopressin / antagonists & inhibitors*
  • Down-Regulation / drug effects
  • Humans
  • Male
  • Polycystic Kidney Diseases / blood*
  • Polycystic Kidney Diseases / drug therapy
  • Tolvaptan
  • von Willebrand Factor / analysis
  • von Willebrand Factor / metabolism*

Substances

  • Benzazepines
  • Blood Coagulation Factors
  • von Willebrand Factor
  • Tolvaptan
  • Deamino Arginine Vasopressin

Associated data

  • ClinicalTrials.gov/NCT01214421